Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.76 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.70 |
| ▸ | CNR2 | P34972 | 3/20 | 0.70 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.58 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16656482 | 0.84 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2CNR2CNR1 | |
| SCHEMBL8648192 | 0.84 | AKR1C3 (0.68) | AKR1C3AKR1C2PTGS2CNR2CNR1 | |
| SCHEMBL6102416 | 0.83 | AKR1C3 (0.84) | AKR1C3AKR1C2PTGS2CNR2CNR1 | |
| SCHEMBL30426824 | 0.83 | PTGS2 (1.00) | AKR1C3AKR1C2PTGS2CNR2HIF1A | |
| SCHEMBL30761037 | 0.83 | AKR1C3 (0.87) | AKR1C3AKR1C2PTGS2CNR2CNR1 | |
| SCHEMBL14086813 | 0.83 | PTGS2 (1.00) | AKR1C3AKR1C2PTGS2CNR2HIF1A | |
| SCHEMBL12628642 | 0.82 | AKR1C3 (0.62) | AKR1C3AKR1C2PTGS2CNR2CNR1 | |
| SCHEMBL10876035 | 0.81 | AKR1C3 (0.76) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| SCHEMBL5645575 | 0.80 | AKR1C3 (0.77) | AKR1C3AKR1C2PTGS2CNR2CNR1 | |
| SCHEMBL8645997 | 0.80 | PLA2G2A (0.83) | PTGS2HIF1ALMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828171-B1 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2014-03-12 | — | — | EP | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| EP-1828171-A2 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006061638-A2 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC5, HDAC11 | AKR1C3 1654/4885AKR1C2 1089/4885PTGS2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.